Send to

Choose Destination
Bull Cancer. 2018 Dec;105 Suppl 1:S50-S58. doi: 10.1016/S0007-4551(18)30390-4.

L’arrivée de l’immunothérapie dans le lymphome de Hodgkin.

[Article in French]

Author information

Service d'onco-hématologie - Hôpital Saint-Louis, AP-HP, Paris, France. Electronic address:
Service d'onco-hématologie - Hôpital Saint-Louis, AP-HP, Paris, France.


Classical Hodgkin lymphoma (HL) is a rare hematological cancer, affecting preferentially young adults. Using a risk-adapted approach, HL has become highly curable (>80%) with front-line chemotherapy in addition with radiotherapy, despite long term significant toxicity. Some patients are primary refractory or relapse after first-line chemotherapy, requiring high dose chemotherapy with serious side effects. Studies of the microenvironment from HL tissue reveal ineffective inflammatory and immune cell infiltrate surrounding Reed-Sternberg cells, involving the Programmed cell Death 1 (PD-1)/PD-ligand-1 checkpoint pathways. Recently, immune checkpoint inhibitors demonstrated high efficacy for relapsed and refractory patients, with a favorable safety profile but indeterminate long term outcome. Guidelines for nivolumab or pembrolizumab treatment in HL remain to be established.


Anti-PD-1; Hodgkin Lymphoma; Immune checkpoint; Immunothérapie; Lymphome; Nivolumab; Pembrolizumab; de Hodgkin; inhibitor

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center